Table 1 Patients’ characteristics
From: Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial
Characteristics | N (%) |
|---|---|
Age, years | |
< 60 | 795 (69.3) |
> 60 | 449 (36.1) |
Histologic grade | |
1 | 8 (0.7) |
2 | 363 (29.6) |
3 | 857 (69.8) |
Menopausal status | |
Premenopause | 446 (35.9) |
Postmenopause | 797 (64.1) |
Estrogen receptor (> 1% cut-off) | |
Negative | 354 (28.5) |
Positive | 890 (71.5) |
Progesterone receptor (> 1% cut-off) | |
Negative | 495 (39.8) |
Positive | 749 (60.2) |
Pathologic T stage | |
pT1 | 763 (61.4) |
pT2 | 450 (36.2) |
pT3 | 28 (2.3) |
pT4 | 1 (0.1) |
Pathologic lymph nodes stage | |
pN0 | 672 (54.0) |
pN1mic | 69 (5.5) |
pN1 | 321 (25.8) |
pN2 | 116 (9.3) |
pN3 | 66 (5.3) |
Arm | |
A Long | 624 (50.2) |
B Short | 620 (49.8) |